MedPath

IDT Australia Ltd

Ownership
-
Employees
1.8K
Market Cap
-
Website
Introduction

IDT Corp. operates as a holding company. The firm engages in the distribution and market of communications and payment services. It operates through the following segments: Fintech, National Retail Solutions, Net2phone, Traditional Communications, and Corporate. The Fintech segment is involved in international money remittance and related value transfer services. The National Retail Solutions segment refers to an operator of a nationwide POS network providing independent retailers with store management software, electronic payment processing, and other ancillary merchant services. The Net2phone segment consists of net2phone's cloud communications and contact center offerings. The Traditional Communications segment includes IDT Digital Payments, which enables customers to transfer airtime and bundles of airtime, messaging, and data to international and domestic mobile accounts, BOSS Revolution Calling, an international long-distance calling service marketed primarily to immigrant communities in the United States and Canada, and IDT Global, a wholesale provider of international voice and SMS termination and outsourced traffic management solutions to telecoms worldwide. The company was founded by Howard S. Jonas in August 1990 and is headquartered in Newark, NJ.

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

12

TGA:12

Drug Approvals

CBD100, 50 mL (396299)

Product Name
CBD100, 50 mL
Approval Date
Sep 23, 2022
TGA

CBD100, 30 mL (396298)

Product Name
CBD100, 30 mL
Approval Date
Sep 23, 2022
TGA

Temozolomide Capsules 5 mg (280375)

Product Name
Temozolomide Capsules 5 mg
Approval Date
Sep 16, 2016
TGA

Temozolomide Capsules 20 mg (280377)

Product Name
Temozolomide Capsules 20 mg
Approval Date
Sep 16, 2016
TGA

Temozolomide Capsules 180 mg (280380)

Product Name
Temozolomide Capsules 180 mg
Approval Date
Sep 16, 2016
TGA

Temozolomide Capsules 140 mg (280379)

Product Name
Temozolomide Capsules 140 mg
Approval Date
Sep 16, 2016
TGA

Temozolomide Capsules 100 mg (280431)

Product Name
Temozolomide Capsules 100 mg
Approval Date
Sep 16, 2016
TGA

Temozolomide Capsules 250 mg (280384)

Product Name
Temozolomide Capsules 250 mg
Approval Date
Sep 16, 2016
TGA

Doxazosin mesilate Tablets 4 mg (238897)

Product Name
Doxazosin mesilate Tablets 4 mg
Approval Date
May 25, 2015
TGA

Doxazosin mesilate Tablets 1 mg (238895)

Product Name
Doxazosin mesilate Tablets 1 mg
Approval Date
May 25, 2015
TGA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

No trials found

News

Ribbon Bio Strengthens Commercial Leadership with Jeff Fitzgerald Appointment as Global Sales Head Amid MiroSynth™ DNA Launch

• Ribbon Bio has appointed Jeff Fitzgerald as Vice President, Global Head of Sales to drive commercial growth as the company launches its first product, MiroSynth™ DNA Molecules. • Fitzgerald brings over a decade of commercial leadership experience from companies including ArcherDx and IQVIA, where he demonstrated success in scaling operations and delivering revenue growth. • MiroSynth™ DNA utilizes Ribbon Bio's proprietary algorithm-driven technology and enzymatic assembly process to deliver highly complex and accurate synthetic DNA for applications in biopharma and life sciences.

© Copyright 2025. All Rights Reserved by MedPath